ClinicalTrials.gg
RecruitingNCT04984291Updated Apr 28, 2026

Zimmer Biomet Shoulder Arthroplasty PMCF

An interventional study of Alliance Glenoid and Identity Stem in Shoulder Fractures, Shoulder Arthritis and Shoulder Osteoarthritis, sponsored by Zimmer Biomet. Recruiting at 17 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Zimmer Biomet · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
584
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Shoulder Fractures by Zimmer Biomet — 7 open to participants now, 9 under way, none of them phase 3. Shoulder Fractures · Zimmer Biomet.

Started
2021
the only one that year
No phase
2 of 12
1 open now
Registered
6th of 12
by date

Among the 12 studies in Shoulder Fractures by Zimmer Biomet, this one is the only one that started in 2021, is one of 2 with no phase, and was the 6th registered.

Shoulder Fractures

113 studies on the registry are indexed under Shoulder Fractures; 30 are open to participants now.

Browse Shoulder Fractures studies →

Open to participants now

7 of the 12 studies in Shoulder Fractures by Zimmer Biomet are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 18 Shoulder Fractures studies recruiting now, 13 (72%) set no upper age limit and 3 (17%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Shoulder Fractures by Zimmer Biomet, or all of them as a file.
02

Study summary

The objectives of this study are to confirm the safety, performance, and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation in primary or revision shoulder arthroplasty. These objectives will be assessed using standard scoring systems, radiographic evidence, and adverse event records. Safety of the system will be assessed by monitoring the frequency an incidence of adverse events.

Read the detailed description

The primary endpoint is defined as survival of the implant at 10 years, which is based on removal or intended removal of at least 1-study implant component and will be determined by using the Kaplan Meier method. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Separate analysis will be done for each arm of the study.

The secondary endpoint is represented by the performance and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation after 2 years, which will be assessed by the American Shoulder and Elbow Surgeons (ASES) shoulder score. The secondary endpoint evaluation will also assess the overall pain, functional performance, quality of life and radiographic parameters of all enrolled study subjects.

03

Conditions studied

  • Shoulder Fractures
  • Shoulder Arthritis
  • Shoulder Osteoarthritis
  • Shoulder Deformity
  • Shoulder Injuries
  • Shoulder Pain

Keywords

  • Total Shoulder Arthroplasty
  • Glenoid
  • Humeral Stem
  • Stem Adapter
  • Humeral Head
  • Humeral Bearing
  • Humeral Trays
  • Head Adapter
  • Reverse
  • Anatomic
  • Hemi
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be 20 years of age or older.
  • Patient must be anatomically and structurally suited to receive shoulder arthroplasty implants.
  • Patient is a candidate for shoulder arthroplasty due to one or more of the following:

    • Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
    • Rheumatoid arthritis.
    • Correction of functional deformity.
    • Fractures of the proximal humerus, where other methods of treatment are deemed inadequate.
    • Difficult clinical management problems, where other methods of treatment may not be suitable or may be inadequate.
  • Patient must be able and willing to complete the protocol required follow-up.
  • Patient must be able and willing to sign the IRB/EC approved .
  • Patient has grossly deficient rotator, (for reverse application)

    • With severe arthropathy and/or
    • Previously failed shoulder joint replacement
  • Patient must have functional deltoid muscle (for reverse application)

Exclusion criteria

Exclusion Criteria:

  • Patient is unwilling or unable to give consent or to comply with the follow-up program.
  • Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study.
  • Patient is known to be pregnant or breastfeeding.
  • Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, and/or anticipated to be non-compliant).
  • Patient is uncooperative or patient with neurologic disorders who is incapable or unwilling to follow directions.
  • Patient has any sign of infection affecting the shoulder joint or in its proximity which may spread to the implant site.
  • Patient has rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram.
  • Patient has any neuromuscular disease compromising the affected limb that would render the procedure unjustifiable.
  • Patient presents with osteoporosis, which in the opinion of the Investigator, may limit the subject's ability to support total shoulder arthroplasty using the study device.
  • Patient has osteomalacia.
  • Patient has a metabolic disorder that may impair bone formation.
  • Patient has deficient rotator cuff.
  • Patient presents with significant injury to the upper brachial plexus.
  • Patient has paralysis of the axillary nerve.
  • Patient has non-functional deltoid or external rotator muscles.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
584 participants (estimated)

Study arms

  • Experimental
    Zimmer Biomet Total Shoulder Arthroplasty System

    Patients who are having primary or revision total shoulder arthroplasty who will receive a Zimmer Biomet Total Shoulder Arthroplasty System.

    Device: Alliance Glenoid · Device: Identity Stem

Interventions

  • DeviceAlliance Glenoid

    Alliance Glenoid used in Primary or Revision Total Shoulder Arthroplasty

    Also known as: Alliance

  • DeviceIdentity Stem

    Identity Shoulder System is intended to be used in anatomic total shoulder arthroplasty, shoulder hemi-arthroplasty, or total reverse shoulder arthroplasty in both Primary or Revision Total Shoulder Arthroplasty

    Also known as: Identity

06

What researchers measure

Primary outcomes

  1. Implant Survivorship at 10 years follow-up (Kaplan Meier)

    Based on removal or intended removal of the device and determined using the Kaplan-Meier method.

    Time frame: 10 years

  2. Frequency and Incidence of Adverse Events (Safety)

    Monitoring the frequency and incidence of adverse events, serious adverse events, adverse device effects, serious adverse device effects, and unanticipated serious adverse device effects as well as device deficiencies.

    Time frame: 10 years

Secondary outcomes

  1. Clinical efficacy of the device is assessed using the American Shoulder and Elbow Surgeons (ASES) Shoulder Score at 2 years follow-up

    Pain, function, and activities of daily living are measured. The ASES scale is 0-100. 100 is the highest score and indicates the greatest function while 0 is the lowest score.

    Time frame: 2 years

  2. Euroqol Patient Quality of life measured at 2 years follow-up (EQ-5D-5L)

    The EuroQol five dimensions questionnaire (EQ-5D-5L) is a five dimensional self-assessment that is comprised of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. These five dimensions can be used to index a subject's health utility on a scale of 0 to 1, where 0 is death and 1 is perfect health. The scoring rule for EQ-5D permits scores less than 0, implying that some health states may be worse than death.

    Time frame: 2 years

  3. Radiographic Performance [Radiolucency] at 2 years follow-up

    X-rays will be evaluated for radiolucency lines to show the number of subjects with radiolucency. Radiolucency refers to structures that are less dense and permit the x-ray beam to pass through them. Radiolucent structures appear dark or black in the radiographic image.

    Time frame: 2 years

  4. Radiographic Performance [Osteolysis] at 2 years follow-up

    X-rays will be evaluated for osteolysis to show the number of subjects with osteolysis. Osteolysis is a progressive condition where bone tissue is destroyed. In this process, bones lose minerals (mostly calcium), softens, degenerates and become weaker.

    Time frame: 2 years

  5. Radiographic Performance [Heterotopic Ossification] at 2 years follow-up

    X-rays will be evaluated for heterotopic ossification to show the number of subjects with heterotopic ossification. Heterotopic ossification refers to the presence of bone in soft tissue where bone normally does not exist (extraskeletal bone).

    Time frame: 2 years

  6. Radiographic Performance [Humeral Component Subsidence] at 2 years follow-up

    X-rays will be evaluated for humeral component subsidence to show the number of subjects with subsidence. Component Subsidence refers to the presence of the device component gradually sinking or caving into the bone structure.

    Time frame: 2 year

  7. Radiographic Performance [Glenoid Component Migration] at 2 years follow-up

    X-rays will be evaluated for glenoid component migration to show the number of subjects with migration. Component migration refers to the presence of the device component gradually moving anteriorly, posteriorly, superiorly, or inferiorly in relation to original placement.

    Time frame: 2 year

07

Study locations

2 of 17 sites recruiting
  • Hoag Orthopedic Institute
    Irvine, California 92618, United States
    Active, not recruiting

    Not enrolling at this site.

  • Panorama Orthopaedic and Spine Center
    Golden, Colorado 80401, United States
    Recruiting
  • Northwestern University
    Chicago, Illinois 60208, United States
    Active, not recruiting

    Not enrolling at this site.

  • Norton Healthcare, Inc
    Louisville, Kentucky 40202, United States
    Terminated

    Not enrolling at this site.

  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
    Active, not recruiting

    Not enrolling at this site.

  • TRIA Orthopaedic Center Research Institute
    Bloomington, Minnesota 55431, United States
    Active, not recruiting

    Not enrolling at this site.

  • Mississippi Sports Medicine and Orthopaedic Center, PLLC
    Jackson, Mississippi 39202, United States
    Active, not recruiting

    Not enrolling at this site.

  • Advance Bone and Joint
    City of Saint Peters, Missouri 63376, United States
    Active, not recruiting

    Not enrolling at this site.

  • Washington University
    St Louis, Missouri 63130, United States
    Active, not recruiting

    Not enrolling at this site.

  • University of Buffalo
    Buffalo, New York 14215, United States
    Active, not recruiting

    Not enrolling at this site.

  • Rothman Institute
    Philadelphia, Pennsylvania 19107, United States
    Active, not recruiting

    Not enrolling at this site.

  • Intermountain Health
    Murray, Utah 84107, United States
    Recruiting
  • Fukui General Hospital
    Fukui, 910-3113, Japan
    Active, not recruiting

    Not enrolling at this site.

  • Iwaki City Medical Center
    Fukushima, 973-8555, Japan
    Active, not recruiting

    Not enrolling at this site.

  • Yuuai Medical Center
    Okinawa, 901-0224, Japan
    Active, not recruiting

    Not enrolling at this site.

  • Kichijoji Minami Hospital
    Tokyo, 180-0003, Japan
    Withdrawn

    Not enrolling at this site.

  • Kensington Private Hospital
    Whangarei, 0112, New Zealand
    Withdrawn

    Not enrolling at this site.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Aug 2033, 144 months after the start.

Of 27 interventional studies with no phase under Shoulder Fractures, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 83. This study's planned 144 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2021
First posted
Jul 30, 2021
StartActual
Jul 28, 2021
Primary completionEst.
Aug 15, 2033
CompletionEst.
Aug 15, 2033
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04984291
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Jul 30, 2021
Start date
Jul 28, 2021
Primary completion
Aug 15, 2033 (estimated)
Completion
Aug 15, 2033 (estimated)
Last update
Apr 28, 2026

Study contacts

Cayla Lafollette, BS
Contact
Cayla.lafollette@zimmerbiomet.com
574 268-8610
Ryan Boylan, MBA
Contact
ryan.boylan@zimmerbiomet.com
Ryan Boylan
study director · Zimmer Biomet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion